Company Information & Drug Savings for Viela Bio Medications

Viela Bio, acquired by Horizon Therapeutics (now Amgen), developed treatments for autoimmune and inflammatory diseases. The company created Uplizna (inebilizumab), an anti-CD19 therapy for neuromyelitis optica spectrum disorder (NMOSD). Viela’s innovative immunology approach continues advancing treatments for rare autoimmune conditions.